Skip to Content
MilliporeSigma

SRCP1 Conveys Resistance to Polyglutamine Aggregation.

Molecular cell (2018-07-22)
Stephanie Santarriaga, Holly N Haver, Adam J Kanack, Alicia S Fikejs, Samantha L Sison, John M Egner, Jonathan R Bostrom, Emily R Seminary, R Blake Hill, Brian A Link, Allison D Ebert, K Matthew Scaglione
ABSTRACT

The polyglutamine (polyQ) diseases are a group of nine neurodegenerative diseases caused by the expansion of a polyQ tract that results in protein aggregation. Unlike other model organisms, Dictyostelium discoideum is a proteostatic outlier, naturally encoding long polyQ tracts yet resistant to polyQ aggregation. Here we identify serine-rich chaperone protein 1 (SRCP1) as a molecular chaperone that is necessary and sufficient to suppress polyQ aggregation. SRCP1 inhibits aggregation of polyQ-expanded proteins, allowing for their degradation via the proteasome, where SRCP1 is also degraded. SRCP1's C-terminal domain is essential for its activity in cells, and peptides that mimic this domain suppress polyQ aggregation in vitro. Together our results identify a novel type of molecular chaperone and reveal how nature has dealt with the problem of polyQ aggregation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thioflavin T, used as stain for amyloid
Sigma-Aldrich
3-Methyladenine, autophagy inhibitor
Sigma-Aldrich
Suplatast tosylate, ≥98% (HPLC)
Sigma-Aldrich
17-(Allylamino)-17-demethoxygeldanamycin, ≥98% (HPLC), solid
Sigma-Aldrich
Poly-L-lysine hydrobromide, mol wt 70,000-150,000, lyophilized powder, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
MG-132, Ready Made Solution, ≥90% (HPLC)